178 related articles for article (PubMed ID: 12126937)
21. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta.
Tee MK; Rogatsky I; Tzagarakis-Foster C; Cvoro A; An J; Christy RJ; Yamamoto KR; Leitman DC
Mol Biol Cell; 2004 Mar; 15(3):1262-72. PubMed ID: 14699072
[TBL] [Abstract][Full Text] [Related]
22. Selective estrogen receptor modulator effects in the rat brain.
Zhou W; Koldzic-Zivanovic N; Clarke CH; de Beun R; Wassermann K; Bury PS; Cunningham KA; Thomas ML
Neuroendocrinology; 2002 Jan; 75(1):24-33. PubMed ID: 11810032
[TBL] [Abstract][Full Text] [Related]
23. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
24. Effect of chronic estradiol, tamoxifen or raloxifene treatment on serotonin 5-HT1A receptor.
Landry M; Di Paolo T
Brain Res Mol Brain Res; 2003 Apr; 112(1-2):82-9. PubMed ID: 12670705
[TBL] [Abstract][Full Text] [Related]
25. Isoform-selective interactions between estrogen receptors and steroid receptor coactivators promoted by estradiol and ErbB-2 signaling in living cells.
Bai Y; Giguére V
Mol Endocrinol; 2003 Apr; 17(4):589-99. PubMed ID: 12554772
[TBL] [Abstract][Full Text] [Related]
26. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta.
Kumar A; Klinge CM; Goldstein RE
Int J Oncol; 2010 May; 36(5):1067-80. PubMed ID: 20372779
[TBL] [Abstract][Full Text] [Related]
27. Differential estradiol and selective estrogen receptor modulator (SERM) regulation of Keratin 13 gene expression and its underlying mechanism in breast cancer cells.
Sheng S; Barnett DH; Katzenellenbogen BS
Mol Cell Endocrinol; 2008 Dec; 296(1-2):1-9. PubMed ID: 18951949
[TBL] [Abstract][Full Text] [Related]
28. Impact of the nuclear receptor coactivator AIB1 isoform AIB1-Delta3 on estrogenic ligands with different intrinsic activity.
Reiter R; Oh AS; Wellstein A; Riegel AT
Oncogene; 2004 Jan; 23(2):403-9. PubMed ID: 14691461
[TBL] [Abstract][Full Text] [Related]
29. The nuclear receptor coactivator PGC-1alpha exhibits modes of interaction with the estrogen receptor distinct from those of SRC-1.
Bourdoncle A; Labesse G; Margueron R; Castet A; Cavaillès V; Royer CA
J Mol Biol; 2005 Apr; 347(5):921-34. PubMed ID: 15784253
[TBL] [Abstract][Full Text] [Related]
30. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists.
Huang HJ; Norris JD; McDonnell DP
Mol Endocrinol; 2002 Aug; 16(8):1778-92. PubMed ID: 12145334
[TBL] [Abstract][Full Text] [Related]
31. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells.
Frasor J; Stossi F; Danes JM; Komm B; Lyttle CR; Katzenellenbogen BS
Cancer Res; 2004 Feb; 64(4):1522-33. PubMed ID: 14973112
[TBL] [Abstract][Full Text] [Related]
32. Structure-function evaluation of ER alpha and beta interplay with SRC family coactivators. ER selective ligands.
Wong CW; Komm B; Cheskis BJ
Biochemistry; 2001 Jun; 40(23):6756-65. PubMed ID: 11389589
[TBL] [Abstract][Full Text] [Related]
33. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo.
Webb P; Nguyen P; Kushner PJ
J Biol Chem; 2003 Feb; 278(9):6912-20. PubMed ID: 12482846
[TBL] [Abstract][Full Text] [Related]
34. The orphan nuclear receptor SHP utilizes conserved LXXLL-related motifs for interactions with ligand-activated estrogen receptors.
Johansson L; Båvner A; Thomsen JS; Färnegårdh M; Gustafsson JA; Treuter E
Mol Cell Biol; 2000 Feb; 20(4):1124-33. PubMed ID: 10648597
[TBL] [Abstract][Full Text] [Related]
35. Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators.
Lopez GN; Webb P; Shinsako JH; Baxter JD; Greene GL; Kushner PJ
Mol Endocrinol; 1999 Jun; 13(6):897-909. PubMed ID: 10379889
[TBL] [Abstract][Full Text] [Related]
36. Current status of selective estrogen receptor modulators (SERMs).
Conzen SD
Cancer J; 2003; 9(1):4-14. PubMed ID: 12602762
[No Abstract] [Full Text] [Related]
37. The terminal substituents of 7α, 6-hexanyl derivatives of estradiol determine their selective estrogen receptor modulator versus agonist activities.
Hoffman KL; Foster EA; Smith CL
Steroids; 2012 Apr; 77(5):496-503. PubMed ID: 22326682
[TBL] [Abstract][Full Text] [Related]
38. Estrogen receptor-alpha interaction with the CREB binding protein coactivator is regulated by the cellular environment.
Jaber BM; Mukopadhyay R; Smith CL
J Mol Endocrinol; 2004 Feb; 32(1):307-23. PubMed ID: 14766010
[TBL] [Abstract][Full Text] [Related]
39. The cardiovascular effects of selective estrogen receptor modulators.
Christodoulakos GE; Lambrinoudaki IV; Botsis DC
Ann N Y Acad Sci; 2006 Dec; 1092():374-84. PubMed ID: 17308162
[TBL] [Abstract][Full Text] [Related]
40. A subfamily of RNA-binding DEAD-box proteins acts as an estrogen receptor alpha coactivator through the N-terminal activation domain (AF-1) with an RNA coactivator, SRA.
Watanabe M; Yanagisawa J; Kitagawa H; Takeyama K; Ogawa S; Arao Y; Suzawa M; Kobayashi Y; Yano T; Yoshikawa H; Masuhiro Y; Kato S
EMBO J; 2001 Mar; 20(6):1341-52. PubMed ID: 11250900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
